Leuprorelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist and peptide active pharmaceutical ingredient used to suppress gonadal hormone production in various hormone-dependent conditions. It is a synthetic analogue of naturally occurring GnRH with enhanced biological stability and prolonged activity.
Leuprorelin initially stimulates pituitary GnRH receptors, increasing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous administration, persistent receptor stimulation causes GnRH receptor desensitization and downregulation, resulting in suppression of LH and FSH secretion and a subsequent reduction in testosterone or estrogen production.
Leuprorelin is a synthetic decapeptide with the molecular formula C59H84N16O12 and a molecular weight of approximately 1209.40 g/mol. Its CAS Number is 53714-98-4.
Leuprorelin is commonly used in pharmaceutical products as leuprorelin acetate. The peptide API requires specialized quality control, including peptide identity, purity, related peptides and biological activity testing.
Leuprorelin acts as a potent GnRH receptor agonist.
Continuous administration initially produces a transient increase in LH and FSH secretion. Continued exposure leads to desensitization of pituitary GnRH receptors, reducing LH and FSH secretion. This ultimately suppresses production of gonadal sex hormones.
The resulting hormonal suppression provides the basis for its use in hormone-dependent conditions.
Leuprorelin is used in approved formulations for conditions including prostate cancer, endometriosis, uterine fibroids and central precocious puberty. It is also used in selected reproductive medicine protocols for controlled suppression of gonadal function.
The precise indication, dosage form and administration route depend on the particular pharmaceutical formulation and regulatory approval in the relevant market.
Leuprorelin API can be evaluated using validated peptide analytical methods for identity, assay, peptide purity, related peptides, degradation products, water content, residual solvents and other applicable quality attributes.
Analytical characterization may include HPLC, mass spectrometry, peptide mapping, amino-acid analysis and other validated chromatographic or spectroscopic methods. Biological activity or potency testing may also be applicable.
Acceptance criteria should be based on the applicable manufacturer's drug-substance specification, Certificate of Analysis and relevant regulatory requirements.
Leuprorelin should be stored under controlled conditions appropriate for a peptide pharmaceutical ingredient. Protection from excessive heat, moisture, direct light and other conditions that may cause peptide degradation is important.
Specific storage and transportation conditions should follow the applicable manufacturer's approved specification.
Leuprorelin API may be supplied for qualified pharmaceutical manufacturing, peptide formulation development, analytical and research applications, subject to applicable quality and regulatory requirements.
Leuprorelin API is available for qualified pharmaceutical and biopharmaceutical development requirements subject to applicable quality and regulatory standards. Customers can request product specifications, Certificate of Analysis, analytical documentation, packaging information and commercial details according to their requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | ≤ 0.5% |
| Total Impurities | NMT 5.0% |
| Water Content | NMT 5.0% |